Medarex Improves In 1995

11 March 1996

- Medarex achieved revenues in the fourth quarter of 1995 of $544,019, up 83.1%. A net loss was recorded of $1.5 million, slightly improved on the 1994 fourth quarter loss of $1.7 million. The loss per share was 14 cents compared to 20 cents. For the full year, Medarex posted revenues of 1.8 million, up 260%. The net loss was $6.5 million, down from $7.2 million in 1994, and the loss per share was 69 cents, compared with $1.00 a year earlier.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight